Cover Image
市場調查報告書

學名藥 (非專利處方藥) 的日本市場

Generic Drugs Market in Japan 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 324488
出版日期 內容資訊 英文 94 Pages
訂單完成後即時交付
價格
Back to Top
學名藥 (非專利處方藥) 的日本市場 Generic Drugs Market in Japan 2015-2019
出版日期: 2015年02月11日 內容資訊: 英文 94 Pages
簡介

學名藥,是在日本的醫藥品市場中收益最為提高的領域之一。日本的學名藥的市場規模,從2014年到2019年之間,預計以8.16%的年複合成長率擴大。

本報告提供日本的學名藥市場的相關分析、各產品及各終端用戶產業市場規模和今後的預測、市場成長因素與課題、主要供應商的簡介等。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 日本概要

第7章 日本的學名藥的核准途徑

  • 原料藥等登記底帳方案
  • 同等性實驗
  • 可靠性審核

第8章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第9章 各類型產品的市場分類

第10章 各治療適用的市場分類

第11章 購買標準

第12章 市場成長因素

第13章 成長因素與其影響

第14章 市場課題

第15章 成長因素與課題的影響

第16章 市場趨勢

第17章 趨勢與其影響

第18章 業者情勢

  • 競爭模式
    • 主要消息
    • M&A
  • 市場佔有率分析
  • 其他卓越供應商

第19章 主要供應商分析

  • Meiji Seika Pharma
  • Nichi-Iko Pharmaceutical
  • Nipro Pharma
  • 澤井製藥
  • Teva Pharmaceutical Industries
  • 東和藥品

第20章 相關報告

目錄
Product Code: IRTNTR5244

About Generic Drugs

A generic drug is a duplicate of brand-name drugs and has the same dosage form, active ingredient(s), potency, route of administration, quality, and intended use as that of branded drugs. Generic drugs enter the market once the patent protection of the original developer expires. Generally, the cost of generic drugs is 50-70 percent lower than that of their brand-name counterparts, while meeting the very same standards of safety, quality, and efficacy as the innovator drugs. Generic drugs help the manufacturer by eliminating the need to develop and market a new drug. As the patent approaches expiration, manufacturers can apply to the FDA for approval to manufacture and sell generic versions of the drug. Generic drugs are equal to and within the bioequivalence range of branded drugs.

TechNavio's analysts forecast the Generic Drugs market in Japan to grow at a CAGR of 8.16 percent over the period 2014-2019.

Covered in this Report

The Generic Drugs market in Japan can be divided into three segments: Generic Prescription Medicines, Super Generics, and Biosimilars. This report covers the present scenario and the growth prospects of the Generic Drugs market in Japan for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the following segments:

  • Generic Prescription Medicines
  • Super Generics
  • Biosimilars

TechNavio's report, the Generic Drugs market in Japan 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape of the Generic Drugs market in Japan and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Vendors

  • Meiji Seika Pharma
  • Nichi-Iko Pharmaceutical
  • Nipro Pharma
  • Sawai Pharmaceuticals
  • Teva Pharmaceutical Industries
  • Towa Pharmaceutical

Other Prominent Vendors

  • Actavis
  • Daiichi Sankyo
  • Daito Pharmaceutical
  • Eisai
  • Fuji Pharma
  • GlaxoSmithKline
  • Hikari Pharmaceutical
  • Hospira
  • Mylan
  • Nihon Generic
  • Nippon Chemipher
  • Nippon Kayaku
  • Nissin Pharmaceutical
  • Ohara Pharmaceutical
  • Pfizer
  • Sandoz
  • Taiyo Yakuhin
  • Takeda Pharmaceutical
  • Zensei Pharmaceutical Industries

Market Driver

  • Increase in Number of Patent Expiries
  • For a full, detailed list, view our report.

Market Challenge

  • Intense Competition among Vendors
  • For a full, detailed list, view our report

Market Trend

  • Increase in M&A
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Country Overview of Japan

07. Approval Pathway of Generic Drugs in Japan

  • 07.1. Master File Scheme for Active Ingredients
  • 07.2. Equivalency Review
  • 07.3. Conformity Audit

08. Market Landscape

  • 08.1. Market Overview
  • 08.2. Market Size and Forecast
  • 08.3. Five Forces Analysis

09. Market Segmentation by Product Category

10. Market Segmentation by Therapeutic Application

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

  • 18.1. Competitive Scenario
    • 18.1.1. Key News
    • 18.1.2. Mergers and Acquisitions
  • 18.2. Market Share Analysis 2014
  • 18.3. Other Prominent Vendors

19. Key Vendor Analysis

  • 19.1. Meiji Seika Pharma
    • 19.1.1. Key Facts
    • 19.1.2. Business Description
    • 19.1.3. Business Segmentation
    • 19.1.4. Business Strategy
    • 19.1.5. Revenue by Business Segmentation
    • 19.1.6. Revenue Comparison 2011 and 2012
    • 19.1.7. Revenue by Geographical Segmentation
    • 19.1.8. Key Information
    • 19.1.9. SWOT Analysis
  • 19.2. Nichi-Iko
    • 19.2.1. Key Facts
    • 19.2.2. Business Description
    • 19.2.3. Business Segmentation
    • 19.2.4. Business Strategy
    • 19.2.5. Revenue by Business Segmentation
    • 19.2.6. Revenue Comparison 2011 and 2012
    • 19.2.7. Revenue by Geographical Segmentation
    • 19.2.8. Key Information
    • 19.2.9. SWOT Analysis
  • 19.3. Nipro Pharma
    • 19.3.1. Key Facts
    • 19.3.2. Business Description
    • 19.3.3. Business Segmentation
    • 19.3.4. Business Strategy
    • 19.3.5. Revenue by Business Segmentation
    • 19.3.6. Revenue Comparison 2011 and 2012
    • 19.3.7. Revenue by Geographical Segmentation
    • 19.3.8. Key Information
    • 19.3.9. SWOT Analysis
  • 19.4. Sawai
    • 19.4.1. Key Facts
    • 19.4.2. Business Description
    • 19.4.3. Business Segmentation
    • 19.4.4. Business Strategy
    • 19.4.5. Revenue by Business Segmentation
    • 19.4.6. Revenue Comparison 2011 and 2012
    • 19.4.7. Revenue by Geographical Segmentation
    • 19.4.8. Key Information
    • 19.4.9. SWOT Analysis
  • 19.5. Teva Pharmaceutical Industries
    • 19.5.1. Key Facts
    • 19.5.2. Business Description
    • 19.5.3. Business Segmentation
    • 19.5.4. Business Strategy
    • 19.5.5. Revenue by Business Segmentation
    • 19.5.6. Revenue Comparison 2011 and 2012
    • 19.5.7. Revenue by Geographical Segmentation
    • 19.5.8. Key Information
    • 19.5.9. SWOT Analysis
  • 19.6. Towa Pharmaceutical
    • 19.6.1. Key Facts
    • 19.6.2. Business Description
    • 19.6.3. Business Segmentation
    • 19.6.4. Business Strategy
    • 19.6.5. Revenue by Business Segmentation
    • 19.6.6. Revenue Comparison 2011 and 2012
    • 19.6.7. Revenue by Geographical Segmentation
    • 19.6.8. Key Information
    • 19.6.9. SWOT Analysis

20. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Country Overview of Japan
  • Exhibit 3: Main Data Required for Generic Drugs Approval
  • Exhibit 4: Generic Drugs Market in Japan Overview
  • Exhibit 5: Generic Drugs Market in Japan 2014-2019 (US$ billion)
  • Exhibit 6: Parameters to Promote the Use of Generic Drugs Ahead
  • Exhibit 7: Generic Drug Market Share of Japan in 2014 (in percent)
  • Exhibit 8: Generic Drugs Market Share of Japan in 2019 (in percent)
  • Exhibit 9: Generic Drugs Market Share of Japan and Global (US$ billion)
  • Exhibit 10: Generic Drugs Market Segmentation by Product Category
  • Exhibit 11: Generic Drugs Market in Japan by Therapeutic Applications
  • Exhibit 12: Patent Expiration of Branded Drugs in Japan
  • Exhibit 13: Medical Costs in Japan (in thousand billion)
  • Exhibit 14: Price Difference of atorvastatin between Originator and Generic in Japan (US$)
  • Exhibit 15: Trends of Aging Population in Japan (in percentage)
  • Exhibit 16: Reviews Conducted for Generic Drugs and Others by Fiscal Year 2008-2012
  • Exhibit 17: Comparison between Applications Filed and Approval in Japan
  • Exhibit 18: Meiji Seika Pharma: Business Segmentation by Revenue 2013
  • Exhibit 19: Meiji Seika Pharma: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 20: Meiji Seika Pharma: Geographical Segmentation
  • Exhibit 21: Nichi-Iko: Business Segmentation by Revenue 2013
  • Exhibit 22: Nichi-Iko: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 23: Nichi-Iko: Geographical Segmentation by Revenue 2013
  • Exhibit 24: Nipro Pharma: Business Segmentation by Revenue 2013
  • Exhibit 25: Nipro Pharma: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 26: Nipro Pharma: Geographical Segmentation by Revenue 2013
  • Exhibit 27: Sawai: Business Segmentation by Revenue 2013
  • Exhibit 28: Sawai: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 29: Sawai: Geographical Segmentation
  • Exhibit 30: Teva Pharmaceutical Industries: Business Segmentation by Revenue 2013
  • Exhibit 31: Teva Pharmaceutical Industries: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 32: Teva Pharmaceutical Industries: Geographical Segmentation by Revenue 2013
  • Exhibit 33: Towa Pharmaceutical: Business Segmentation by Revenue 2013
  • Exhibit 34: Towa Pharmaceutical: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 35: Towa Pharmaceutical: Geographical Segmentation
Back to Top